GUBRA posts record Q3 as partner payments and CRO margins climb
GUBRA credited partner milestone payments and stronger CRO profitability for its third-quarter results, and said GUB-UCN2 has entered Phase 1/2a trials.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, GUBRA reported third-quarter results at a record level. The main contributor was milestone income from partners tied to Phase 2 stages, amounting to $50 million and EUR 10 million.
Revenue from the CRO division rose 6%, and its EBIT margin reached 25%. The company narrowed its full-year 2026 CRO guidance and lowered its biotech cost outlook. GUB-UCN2 moved into Phase 1/2a, while two partnered obesity programs also made progress.
why it matters
For investors, the record quarter rests largely on one-off payments rather than recurring sales, so the longer-term picture depends on whether CRO growth holds up in coming periods.
market impact
GUBRA shares: one-off partner payments and CRO gains support the company's reported results
tags
instruments
sources
- GUBRA: Partner milestones drove record-level Q3 earnings as CRO profitability improved and trials advanced — TradingView, 6 November 2026 at 06:03 UTC
- GUBRA: Partner milestones lifted Q3 results as CRO profitability improved and the pipeline advanced — TradingView, 6 November 2026 at 06:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗